Author:
YOSHIOKA Akira,SHIRAHATA Akira,FUKUTAKE Katsuyuki,KAMIYA Tadashi,FUJIMAKI Michio
Publisher
Japanese Society on Thrombosis and Hemostasis
Reference21 articles.
1. 1) Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ, Kasper CK, Kernoff PBA, Levine PH, Lusher JM, Mannucci PM, Scharrer I, MacKenzie MA, Pancham N, Kuo HS, Allred RU, and the recombinant factor VIII study group: Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Eng J Med 323 : 1800-1805, 1990.
2. 2) Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, for The Kogenate Previously Untreated Patient Study Group: Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A--Safety, efficacy, and development of inhibitors. N Eng J Med 328 : 453-459, 1993.
3. 3) Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M: A multicenter study of recombinant factor VIII (recombinate) : safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 83 : 2428-2435, 1994.
4. 4) Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T and the members of the FVIII-LFB and Recombinat FVIII study groups: Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107 : 46-51, 2006.
5. Clinical Evaluation of a Recombinant Factor VIII Preparation (Kogenate) in Previously Untreated Patients with Hemophilia A